SCHEMBL2324939

SCHEMBL2324939

Oc1cccc2c1[nH]c1ccc(Br)cc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 4/20 1.00
PIM3 Q86V86 2/20 0.50
CCNB2 O95067 2/20 0.47
CDK1 P06493 2/20 0.47
CCNB1 P14635 2/20 0.47
CCNB3 Q8WWL7 2/20 0.47
GSK3B P49841 2/20 0.47
PIM1 P11309 1/20 0.46
CCNE2 O96020 1/20 0.46
CDK4 P11802 1/20 0.46
CCND1 P24385 1/20 0.46
CCNE1 P24864 1/20 0.46
CDK2 P24941 1/20 0.46
GABRP O00591 1/20 0.44
GABRD O14764 1/20 0.44
GABRA1 P14867 1/20 0.44
GABRB1 P18505 1/20 0.44
GABRG2 P18507 1/20 0.44
GABRB3 P28472 1/20 0.44
GABRA5 P31644 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27587648 0.86 AR (0.76) ARPIM3CCNB2CDK1CCNB1
SCHEMBL28761777 0.82 AR (0.70) ARCCNB2CDK1CCNB1CCNB3
SCHEMBL25223297 0.82 AR (0.70) ARPIM3CCNB2CDK1CCNB1
SCHEMBL28785549 0.79 AR (0.66) ARPIM3CCNB2CDK1CCNB1
SCHEMBL17950642 0.79 AR (0.66) ARPIM3CCNB2CDK1CCNB1
SCHEMBL28363616 0.79 AR (0.66) ARPIM3CCNB2CDK1CCNB1
SCHEMBL27919630 0.79 AR (0.66) ARGABRPGABRDGABRA1GABRB1
SCHEMBL4055057 0.79 AR (0.66) ARCDK5CDK5R1CHUKMEN1
SCHEMBL1298075 0.79 PIM3 (0.71) ARPIM3CCNB2CDK1CCNB1
SCHEMBL30972538 0.79 PIM3 (0.71) ARPIM3CCNB2CDK1CCNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170121285-A1 Selective androgen receptor modulators RADIUS HEALTH INC (US) 2017-05-04 US claimed
US-20130041007-A1 Selective Androgen Receptor Modulators RADIUS HEALTH, INC. 2013-02-14 US claimed
EP-2531029-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS Radius Health, Inc. (US) 2012-12-12 EP claimed
WO-2011097496-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH, INC. (US) 2011-08-11 WO claimed
US-20170121285-A1 Selective androgen receptor modulators RADIUS HEALTH INC (US) 2017-05-04 US disclosed
US-20170121285-A1 Selective androgen receptor modulators RADIUS HEALTH INC (US) 2017-05-04 US disclosed
US-20170121285-A1 Selective androgen receptor modulators RADIUS HEALTH INC (US) 2017-05-04 US disclosed
EP-2531029-B1 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH INC (US) 2016-10-19 EP disclosed
EP-2531029-B1 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH INC (US) 2016-10-19 EP disclosed
US-20150266821-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH INC (US) 2015-09-24 US disclosed
US-20150266821-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH INC (US) 2015-09-24 US disclosed
US-20150266821-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH INC (US) 2015-09-24 US disclosed
US-8987319-B2 Selective androgen receptor modulators RADIUS HEALTH, INC. (US) 2015-03-24 US disclosed
US-8987319-B2 Selective androgen receptor modulators RADIUS HEALTH, INC. (US) 2015-03-24 US disclosed
US-20130041007-A1 Selective Androgen Receptor Modulators RADIUS HEALTH, INC. 2013-02-14 US disclosed
US-20130041007-A1 Selective Androgen Receptor Modulators RADIUS HEALTH, INC. 2013-02-14 US disclosed
US-20130041007-A1 Selective Androgen Receptor Modulators RADIUS HEALTH, INC. 2013-02-14 US disclosed
EP-2531029-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS Radius Health, Inc. (US) 2012-12-12 EP disclosed
WO-2011097496-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH, INC. (US) 2011-08-11 WO disclosed
WO-2011097496-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH, INC. (US) 2011-08-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170121285-A1 Selective androgen receptor modulators AR, SHBG, FSHR AR 1/4885PIM3 3914/4885CCNB2 604/4885
US-20150266821-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS AR, SHBG, FSHR AR 1/4885PIM3 3886/4885CCNB2 603/4885
US-20130041007-A1 Selective Androgen Receptor Modulators AR, SHBG, GPR119 AR 1/4885PIM3 3579/4885CCNB2 659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.